Pancreatic Cancer Research

GrantR44National Cancer Institute

Development of Claudin MAbs for Treating Solid Tumors

Activity
R44
Institute
National Cancer Institute
Fiscal years counted
2022–2024
Amount counted
$1,703,866

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Abstract public domain (NIH RePORTER)

ABSTRACT Solid tumors lead to 580,000 deaths annually in the US, and safe and effective therapeutics for many late- stage solid tumors are lacking. Ovarian cancer alone kills 14,000 people each year, and many patients do not respond to currently available treatments. The tight junction protein Claudin 6 (CLDN6) is a validated therapeutic target for many solid tumor types, including ovarian, endometrial, testicular, gastric, and pancreatic cancer. CLDN6 is differentially expressed on cancer cells with almost no expression in normal, healthy tissue. Despite being an attractive target, therapeutic MAbs targeting CLDN6 are difficult to discover due to an absolute need for high specificity. There are 26 human CLDN family members in total and most are broadly expressed and highly conserved, making drug specificity when targeting the CLDNs critically important but especially challenging. The extracellular region of CLDN6 closely resemble the widely expressed CLDN9 (3 amino acids different). The few CLDN6 MAbs discovered by others have demonstrated significant binding to other CLDN family members and most have now been halted in development. Here, we will develop a CLDN6 therapeutic for solid tumors.

Public health relevance public domain (NIH RePORTER)

PROJECT NARRATIVE This proposal will contribute to public health and the treatment of human disease by resulting in a therapeutic against CLDN6 for the treatment of late-stage solid tumors. Solid tumors kill 580,000 Americans annually, and there is an unmet need for safe and effective treatments for patients with late-stage ovarian, endometrial, testicular, gastric, and pancreatic cancers.